FindTrial
Sign In

Efficacy and safety of factor VIIa eptacog alfa, Novoseven on rebleeding after surgery for spontaneous supratentorial intracerebral, hemorrhage. A randomized, controlled, open-label, investigator-blinded pilot study.

Efficacy and safety of factor VIIa eptacog alfa, Novoseven on rebleeding after surgery for spontaneous supratentorial intracerebral, hemorrhage. A randomized, controlled, open-label, investigator-blinded pilot study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-003083-36-IT
Enrollment
Unknown
Registered
2007-01-15
Start date
2004-09-27
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prevention of re-bleeding after surgery for spontaneous supratentorial intracerebral hemarrage.

Interventions

Trade Name: NOVOSEVEN*IV 1,2MG(60KUI)+2,2M Pharmaceutical Form: Powder and solvent for solution for injection CAS Number: 102786-61-8 Concentration unit: IU international unit(s) Concentration type: e

Sponsors

OSPEDALE POLICLINICO S. MATTEO
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026